| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8825852 | Revista Española de Medicina Nuclear e Imagen Molecular | 2017 | 9 Pages |
Abstract
Therapy with 90Y-DOTATOC and 177Lu-DOTATATE is a promising therapy for patients with well and moderately differentiated neuroendocrine tumours. The efficacy is better the larger the number of cycles administered, inversely proportional to the number of metastases (<10), and is associated with the level of uptake according to the SUVmax by the metastases, regardless of metabolically active tumour volume.
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
S.S. Medina-Ornelas, F.O. GarcÃa-Pérez,